DeCure's autonomous Longevity AI scientist is researching a drug-repurposing hypothesis for age related macular degeneration 6 — screening already-approved drugs against its 2-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleAge related macular degeneration 6 maps to a 2-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for age related macular degeneration 6 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
rhodopsin (RHO) — RHO is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet apo structuredrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 5W0P · 3.013 Å · ligand none (apo structure). Experimental structure, not a prediction.
What the evidence adds up to
In a 2014 mouse model of subretinal fibrosis, which mimics late-stage neovascular age-related macular degeneration, interleukin-6 mRNA rose about 12-fold two days after fibrosis induction, and IL-6 protein reached 67.33 pg/mg at the same time point. Blocking the IL-6 receptor with the monoclonal antibody MR16-1 reduced the subretinal fibrosis area by 48% compared to control animals at day 7. The authors concluded that IL-6 signalling may contribute to subretinal fibrogenesis and that IL-6 receptor inhibition might be a novel treatment for advanced neovascular AMD. No human data were provided.
A 2020 study tested lamivudine (3TC), a nucleoside reverse transcriptase inhibitor, against Alu RNA-induced damage in cultured human retinal pigment epithelium cells and in mouse RPE cells. Alu RNA is a long noncoding RNA whose accumulation is thought to activate the NLRP3 inflammasome and drive RPE cell death in geographic atrophy, the dry form of late-stage AMD. In both human and mouse RPE cells, 3TC markedly reduced Alu RNA-induced expression of the proinflammatory cytokines IL-18 and IL-1β compared to a negative control. In human RPE cells, 3TC also suppressed Alu RNA-induced expression of the senescence marker p16INK4a. The authors suggested that Alu RNA contributes to RPE senescence and that 3TC can suppress this process, but the study was limited to cell culture and mouse experiments.
A 2017 review summarised known environmental and genetic risk factors for dry (non-neovascular) AMD but did not report any new experimental results or drug interventions. It noted that AMD is a multifactorial disease involving both genetic variants and environmental factors.
What is still missing: no human clinical trial data for either IL-6 receptor blockade or lamivudine in AMD patients; no evidence that either drug slows vision loss or prevents progression to advanced stages; no information on dosing, safety, or tolerability in the AMD population; and no stratification by genetic or inflammatory subtypes that might predict response.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
PubMed · 2014 · 19 citations · open access
Interleukin-6 receptor blockade suppresses subretinal fibrosis in a mouse model.
AbstractAIM: To determine the involvement of the interleukin (IL)-6 with the development of experimental subretinal fibrosis in a mouse model. METHODS: Subretinal fibrosis was induced by subretinal injection of macrophage-rich peritoneal exudate cells and the local expression of IL-6 was assessed by quantitative real-time reverse transcription-polymerase chain reaction (RT-PCR) and enzyme-linked immunosorbent assay (ELISA) at various time points. In addition, we investigated the effect of IL-6 receptor (IL-6R) monoclonal antibody (MR16-1) on subretinal fibrosis development. RESULTS: IL-6 mRNA level was significantly elevated at 1d after subretinal fibrosis induction and increased further to about 12-fold at 2d, reaching the peak. The result of ELISA showed that IL-6 protein was not detected in naive mice. At 2d after subretinal fibrosis induction, IL-6 protein level was upregulated to 67.33±14.96 pg/mg in subretinal fibrosis mice. MR16-1 treatment resulted in a reduced subretinal fibrosis area by 48% compared to animals from control group at 7d. CONCLUSION: Our results indicated that IL-6 signaling may contribute to the pathogenesis of subretinal fibrogenesis and IL-6R inhibition may provide an effective, novel treatment of advanced and late-stage neovascular age-related macular degeneration.
Lamivudine Inhibits<i>Alu</i>RNA-induced Retinal Pigment Epithelium Degeneration via Anti-inflammatory and Anti-senescence Activities
AbstractPurpose: Accumulation of the long noncoding Alu element RNA activates the NLRP3 inflammasome and leads to retinal pigment epithelium (RPE) cell death, a key event in the pathogenesis of geographic atrophy during late-stage age-related macular degeneration. Lamivudine (3TC) is a nucleoside analog reverse transcriptase inhibitor known to inhibit the NLRP3 inflammasome. Currently, the intracellular response of the senescence marker p16Ink4a to the long noncoding RNA is being actively studied. The present study aimed to assess the efficacy of 3TC against Alu RNA-induced RPE inflammation and senescence by evaluating changes in expression of the proinflammatory cytokines IL-18 and IL-1β and of p16INK4a in RPE cells. Methods: Cultured human RPE cells and in vivo mouse RPE cells were transfected with an in vitro-transcribed Alu RNA, and changes in IL-18, IL-1β, and p16Ink4a expression measured in the presences of 3TC or 3,4-(M)CA as a negative control. Results: Treatment with 3TC markedly reduced Alu RNA-induced expression of IL-18 and IL-1β in human and mouse RPE cells compared with the negative control. Further, Alu RNA-induced p16INK4a expression was suppressed by 3TC in human RPE cells. Conclusions: Our data suggest that Alu RNA accumulation contributes to RPE cell senescence in age-related macular degeneration and that this pathogenic process can be suppressed by 3TC. Translational Relevance: Further verifying this study leads to potential targets for age-related macular degeneration therapy.
Genetic and Risk factors in Dry-Form (Non-Neovascular) Age-Related Macular Degeneration
AbstractAge-related macular degeneration (AMD) is the leading cause of severe visual impairment in older persons. AMD is a multifactorial complex disease that both genetic and many environmental factors play roles in its etiopathogenesis. In recent years, advances in genetic studies have led to the detection of many genetic variants that play a role in the pathogenesis of AMD. This review summarized the environmental and genetic risk factors of AMD.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
